Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ADH1B | P00325 | 2/20 | 0.35 |
| ▸ | ADH1C | P00326 | 2/20 | 0.35 |
| ▸ | ADH1A | P07327 | 2/20 | 0.35 |
| ▸ | ADH7 | P40394 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11293582 | 0.92 | LPAR1 (0.49) | LPAR1LPAR3LPAR2USP2ADH1B | |
| SCHEMBL11293584 | 0.92 | LPAR1 (0.49) | LPAR1LPAR3LPAR2USP2ADH1B | |
| SCHEMBL24207972 | 0.85 | FAAH (0.50) | LPAR1LPAR3 | |
| SCHEMBL24209609 | 0.82 | PLA2G2C (0.48) | LPAR1LPAR3LPAR2USP2TSHR | |
| SCHEMBL3491028 | 0.81 | ALDH1A1 (0.52) | — | |
| SCHEMBL3491031 | 0.81 | ALDH1A1 (0.52) | — | |
| SCHEMBL7679115 | 0.81 | TSHR (0.41) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL5510607 | 0.80 | LPAR1 (0.37) | LPAR1LPAR3LPAR2USP2TSHR | |
| SCHEMBL11498364 | 0.79 | TSHR (0.40) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL18405448 | 0.79 | SPHK1 (0.41) | LPAR1LPAR3LPAR2USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346820-B2 | HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands | PURDUE RESEARCH FOUNDATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150072958-A1 | HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS | PURDUE RESEARCH FOUNDATION | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072958-A1 | HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS | PREP, DPEP1, BACE1 | LPAR1 776/4885LPAR3 1004/4885LPAR2 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.